SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharmaceutical Industries gains on acquiring 100% stake in Libra Merger

03 Jan 2024 Evaluate

Sun Pharmaceutical Industries is currently trading at Rs. 1298.80, up by 2.40 points or 0.19% from its previous closing of Rs. 1296.40 on the BSE.

The scrip opened at Rs. 1297.85 and has touched a high and low of Rs. 1304.10 and Rs. 1291.20 respectively. So far 30706 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1304.10 on 03-Jan-2024 and a 52 week low of Rs. 922.55 on 22-May-2023.

Last one week high and low of the scrip stood at Rs. 1304.10 and Rs. 1249.80 respectively. The current market cap of the company is Rs. 310761.87 crore.

The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 36.44% and 9.07% respectively.

Sun Pharmaceutical Industries has acquired 100% of shares of Libra Merger, a company incorporated in Israel. The objective of acquisition is to facilitate consolidation of business in Israel. Earlier, the company’s specialty product Ilumetri had been included in category B of China's national reimbursement drug list. Ilumetri is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Sun Pharmaceutical Industries is among the largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Sun Pharma Inds. Share Price

1668.00 -7.20 (-0.43%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×